Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 273

Sort by

Sort Order Select

Journal Articles

Association between ABO haplotypes and the risk of venous thrombosis: impact on disease risk estimation

Blood (2021) 137 (17): 2394–2402.

https://doi.org/10.1182/blood.2020008997

Published: 2021

Includes: Supplemental data

Journal Articles

Genetic Association Studies of Red Blood Cell Transfusion Related Alloimmunization: A Systematic Review and Meta-Analysis

Jorn Gerritsma, MD, Ilja Oomen, BSc, Sanne Meinderts, PhD, C. Ellen van der Schoot, MD PhD, Bart J. Biemond, MD PhD, Johanna G van der Bom, MD PhD, Karin Fijnvandraat, MD PhD

Blood (2019) 134 (Supplement_1): 2459.

https://doi.org/10.1182/blood-2019-128199

Published: 2019

Journal Articles

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Blood (2019) 134 (Supplement_1): 5474.

https://doi.org/10.1182/blood-2019-126698

Published: 2019

Journal Articles

Prospective Identification of Acute Myeloid Leukemia Patients Who Benefit from Gene-Expression Based Risk Stratification

Diego Chacon, PhD, Ali Braytee, PhD, Yizhou Huang, PhD, Julie Thoms, PhD, Shruthi Subramanian, BSc, Maria Cristina Sauerland, Stefan K. Bohlander, MD, Jan Braess, MD, Bernhard J. Wörmann, MD, Wolfgang E. Berdel, MD, Wolfgang Hiddemann, MD PhD, Bogdan Gabrys, PhD, Klaus H. Metzeler, MD, Tobias Herold, MD, John Pimanda, MBBS, PhD, Dominik Beck, PhD

Blood (2019) 134 (Supplement_1): 1397.

https://doi.org/10.1182/blood-2019-129519

Published: 2019

Journal Articles

Impact of Somatic Mutations on Outcome in Patients > 60 Years Old with Newly Diagnosed AML Treated with Response-Adapted Sequential Azacitidine and Induction Chemotherapy within the DRKS00004519 Trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO)

Nadja Jaekel, Susann Schulze, MD, Udo Siebolts, MD, Anja Haak, PhD, Nikolaos Pazaitis, MD, Michael Cross, PhD, Dietger Niederwieser, MD, Mathias Hänel, MD, Georg Maschmeyer, MD, Maxi Wass, MD, Lukas Heukamp, MB PhD, Roopika Menon, Miriam Bertrand, Claudia Wickenhauser, MD, Oana Brosteanu, PhD, Haifa Kathrin Al-Ali, MD

Blood (2019) 134 (Supplement_1): 1420.

https://doi.org/10.1182/blood-2019-127865

Published: 2019

Journal Articles

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Sabine Khalife-Hachem, Khalil Saleh, MD, Florence Pasquier, MD PhD, Anthony Tarabay, Cyril Quivoron, Sophie Cotteret, Christophe Willekens, MD, Veronique Saada, Ines-Maria Vaz-Luis, Suzette Delaloge, Alexandra Leary, Hana Raslova, PhD, Filippo Rosselli, Olivier Caron, Iléana Antony-Debre, PhD, Eric Solary, MD PhD, Stephane de Botton, MD PhD, Christophe Marzac, MD, Jean-Baptiste Micol, MD

Blood (2019) 134 (Supplement_1): 3722.

https://doi.org/10.1182/blood-2019-126872

Published: 2019

Journal Articles

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Kara Cicero, MD MPH, Mark L Heaney, Todd L. Rosenblat, MD MS, Nicole Lamanna, MD, Joseph G. Jurcic, MD, Mark G. Frattini, MD PhD, Daniel J. Lee, MD

Blood (2019) 134 (Supplement_1): 3899.

https://doi.org/10.1182/blood-2019-130203

Published: 2019

Journal Articles

Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts

Douglas R. A. Silveira, Lynn Quek, MD PhD, Anna Corby, B.Sc., Juan L Coelho-Silva, BSc, MSc, Diego A Pereira-Martins, MSc, Grant Vallance, B.Sc., PhD, Benjamin Brown, B.Sc., PhD, Luciana Nardinelli, M.Sc, Wellington F Silva, MD, Elvira DRP Velloso, MD PhD, Fabiola Traina, MD PhD, Andy Peniket, MD, Paresh Vyas, MD PhD, Eduardo M Rego, MD PhD, Israel Bendit, MD PhD, Vanderson Rocha, MD PhD

Blood (2019) 134 (Supplement_1): 2602.

https://doi.org/10.1182/blood-2019-130726

Published: 2019

Journal Articles

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

Eugene C Kim, PhD, Jinzhen Fan, PhD, Christopher R Bolen, PhD, Alexandra Bazeos, MD PhD FRCPath, Yanwen Jiang, PhD, Sandhya Balasubramanian, MS, Rama Balakrishnan, PhD, Andrea Knapp, PhD, Kathryn Humphrey, BSc, Tina G Nielsen, MD PhD, Jeffrey M. Venstrom, MD PhD, Genevive Hernandez, PhD, Joseph N Paulson, PhD

Blood (2019) 134 (Supplement_1): 2788.

https://doi.org/10.1182/blood-2019-124687

Published: 2019

Journal Articles

The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment

Ann-Kathrin Eisfeld, MD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MD PhD, Deedra Nicolet, MS, Alice S. Mims, MD, Dimitrios Papaioannou, MD, Christopher J. Walker, PhD, James S. Blachly, MD, Sophia E. Maharry, Andrew J. Carroll, PhD, Richard M. Stone, MD, Bayard L Powell, MD, Albert de la Chapelle, MD PhD, Eunice S. Wang, MD, Jonathan E. Kolitz, MD, John C. Byrd, MD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 2681.

https://doi.org/10.1182/blood-2019-130076

Published: 2019

Journal Articles

Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1 - RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG)

Blood (2019) 134 (Supplement_1): 2740.

https://doi.org/10.1182/blood-2019-125584

Published: 2019

Journal Articles

A Novel Machine Learning Derived Genomics-Based Scoring System Is Highly Predictive of Outcome in Core Binding Factor Acute Myeloid Leukemia

Nikhil Patkar, MD, Chinmayee Kakirde, Anam Fatima Shaikh, Shrinidhi Nathany, MD, Gaurav Chatterjee, MD, Prashant Tembhare, MD, Dhanlaxmi Lalit Shetty, PhD, Anant Gokarn, MD, Sachin Punatar, MBBS,MDDM MDcal Oncology, Avinash Bonda, MD DM, Lingaraj Nayak, MDDM MDcal Oncology, Hasmukh Jain, MD DM, Navin Khattry, MD DM MDcal Oncology, Bhausaheb Bagal, MD DM, Manju Sengar, MD DM, Sumeet Gujral, MD, Papagudi Ganesan Subramanian, MD

Blood (2019) 134 (Supplement_1): 2710.

https://doi.org/10.1182/blood-2019-128500

Published: 2019

Journal Articles

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 3317.

https://doi.org/10.1182/blood-2019-125780

Published: 2019

Journal Articles

Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort

Henry Wood, MBBS, Katy Sanchez, BSc, MSc, Victoria Potter, MBBS, BSc, FRACP, FRCPA, Austin Kulasekararaj, MD MRCP, FRCPath, Hugues de Lavallade, MD PhD, Deborah Yallop, MBBS, FRCP, FRCPath, PhD, Shireen Kassam, MBBS, FRCPath, PhD, Robin M. Ireland, MBBS, FRCP, FRCPath, Antonio Pagliuca, MBBS, MA, FRCP, FRCPath, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Alan Dunlop, BSc, MSc

Blood (2019) 134 (Supplement_1): 4566.

https://doi.org/10.1182/blood-2019-131711

Published: 2019

Journal Articles

Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization

Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Daniel J. Landsburg, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Elise A. Chong, MD, James N. Gerson, MD, Stefan K. Barta, MD MRCP, MS, Sunita Dwivedy Nasta, MD

Blood (2019) 134 (Supplement_1): 5261.

https://doi.org/10.1182/blood-2019-130039

Published: 2019

Journal Articles

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

David I Marks, MBBS, PhD FRCPath, Amy A. Kirkwood, MSc, Clare J Rowntree, MBBS, PhD FRCP, FRCPath, Melanie Aguiar, BSc, Katharine E Bailey, MBBS, FRCPath, MA, MRCP, Brendan Beaton, MD, Laura Clifton-Hadley, PhDBSc, Emma Lawrie, BSc, SooWah Lee, MSc, Andrew K McMillan, FRCP, Anthony V. Moorman, PhD, Rachel J. Mitchell, MSc, Pip Patrick, PhDMSc,MA, Tobias F Menne, MD PhD FRCPath, Paul Smith, Bela Wrench, MBBS, MD MRCP, FRCPath, Krisztina Zuborne Alapi, MSc, Adele K. Fielding, MBBS,PhDFRCP,FRCPath

Blood (2019) 134 (Supplement_1): 739.

https://doi.org/10.1182/blood-2019-123374

Published: 2019

Journal Articles

Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

Naomi Michels, BSc, Judith M. Boer, PhD, Marta Lopez-Yurda, PhD, Hester A. De Groot-Kruseman, PhD, Vincent van der Velden, PhD, Anthony V. Moorman, Amir Enshaei, PhD, Ajay Vora, Rosemary Sutton, BSc MSc PhD, Toby Trahair, PhD, Luciano Dalla-Pozza, MBBS FRACP, Rob Pieters, MDPhDMSc, Michel C Zwaan, MD PhD, Monique L. Den Boer, PhD

Blood (2019) 134 (Supplement_1): 827.

https://doi.org/10.1182/blood-2019-124290

Published: 2019

Journal Articles

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Luca L.G. Janssen, MD, Theresia M. Westers, PhD, Jeroen Rovers, MD PhD, Peter Valk, PhD, Jacqueline Cloos, PhD, Tanja D. de Gruijl, PhD, Arjan A. Van de Loosdrecht, MD PhD

Blood (2019) 134 (Supplement_1): 1381.

https://doi.org/10.1182/blood-2019-127881

Published: 2019

Journal Articles

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

Wellington F Silva, MD, Lidiane Inês Da Rosa, MD, Fernanda S Seguro, MD, Douglas R. A. Silveira, Luciana Nardinelli, M.Sc, Valeria Buccheri, MD PhD, Elvira DRP Velloso, MD PhD, Vanderson Rocha, MD PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 1354.

https://doi.org/10.1182/blood-2019-127202

Published: 2019

Journal Articles

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Blood (2019) 134 (Supplement_1): 1355.

https://doi.org/10.1182/blood-2019-125623

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Association between ABO haplotypes and the risk of venous thrombosis: impact on disease risk estimation

Genetic Association Studies of Red Blood Cell Transfusion Related Alloimmunization: A Systematic Review and Meta-Analysis

Risk-Adapted, Ofatumumab-Based Chemoimmunotherapy and Maintenance in Treatment-Naïve CLL: A Phase II Study

Prospective Identification of Acute Myeloid Leukemia Patients Who Benefit from Gene-Expression Based Risk Stratification

Impact of Somatic Mutations on Outcome in Patients > 60 Years Old with Newly Diagnosed AML Treated with Response-Adapted Sequential Azacitidine and Induction Chemotherapy within the DRKS00004519 Trial (RAS-AZIC) of the East German Study Group of Hematology and Oncology (OSHO)

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Combination Thioguanine and Decitabine Is Highly Active in Patients with Advanced Myeloid Malignancies: A Single Institution Experience

Combining Clinical Features with Genetic Factors Improves Survival Prediction for Adults with Acute Myeloid Leukemia: Validation of a New Score System in 3 Cohorts

Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL

The 2017 European Leukemianet Genetic Risk Classification Performs Poorly in Older Patients with Acute Myeloid Leukemia (AML) and Should be Refined to Identify Patients Requiring Additional or Alternative Treatment

Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1 - RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG)

A Novel Machine Learning Derived Genomics-Based Scoring System Is Highly Predictive of Outcome in Core Binding Factor Acute Myeloid Leukemia

Prognostic Impact of a Composite Genetic Profile Defined By Cytogenetics and Next Generation Sequencing at Diagnosis on Treatment Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia

Post-Transplant Flow Cytometry MRD Predicts Relapse in a Real World AML Cohort

Clinical Outcomes of Non-Hodgkin Lymphoma Patients on Acalabrutinib Including Off-Label Utilization

First Analysis of the UKALL14 Phase 3 Randomised Trial to Determine If the Addition of Rituximab to Standard Induction Chemotherapy Improves EFS in Adults with Precursor B-ALL (CRUK/09/006)

Minimal Residual Disease and IKZF1 As Predictors of Relapse, and Increased Treatment Related Mortality in Down Syndrome Acute Lymphoblastic Leukemia: A Unique and Large International Matched Case-Control Study

Durable Responses and Survival in High Risk AML and MDS Patients Treated with an Allogeneic Leukemia-Derived Dendritic Cell Vaccine

Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults

CPX-351 Induces Deep Response and Suppress the Impact of Poor Prognosis Mutations ( TP53, ASXL1, RUNX1 and EVI1 ) Defined By ELN-2017 in t-AML and MRC AML: A Report from a Multicentric French Cohort

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only